Bristol Myers Squibb adopts Nvidia's latest AI supercomputing platform for drug discovery

Pharmaceutical company becomes first life sciences organisation to deploy DGX SuperPOD with Vera Rubin architecture

Credit: Motorolka/Shutterstock

The new Vera Rubin-based DGX SuperPOD will expand Bristol Myers Squibb's AI capabilities as the company seeks to accelerate drug discovery through large-scale computing

Register for FREE to keep reading

Join 12,000+ scientists, engineers, and IT professionals driving innovation through informatics, HPC, and simulation with:

Insights into HPC, AI, lab informatics & data
Curated content for life sciences, engineering & academia
Access to Breakthroughs: real-world computing success
Free reports & panels, including the Lab Informatics Guide
White Papers & software updates for smarter research

Sign up now

Already a member? Log in here

Your data is protected under our privacy policy.

The 2026 storage survey: strategies for AI and data-intensive research

Scientific Computing World and Seagate are inviting research computing professionals to share how they're preparing storage infrastructure for the demands of AI and data-intensive science. Contribute to the 2026 Storage Survey and help benchmark the future of research data management.